VISTAGEN THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

VTGN

Item 8.01 Other Events.

On October 14, 2021, VistaGen Therapeutics, Inc. issued a press release to announce the initiation of a Phase 2A clinical trial to evaluate the efficacy, safety and tolerability of PH94B as a potential treatment of anxiety in adults with Adjustment Disorder with Anxiety. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

© Edgar Online, source Glimpses